Wegovy may significantly reduce hospital admissions for any cause and overall length of stay, according to a new analysis of data from Novo Nordisk’s phase 3 SELECT trial.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Wegovy reduces all-cause admissions: 3 study findings
